Poor outcome of two children with relapsed state stage IV alveolar rhabdomyosarcoma after allogeneic stem cell transplantation.
The authors report on 2 boys, 11(1/2) and 13 years old, who received allogeneic stem cell transplantation (alloSCT) from their HLA-identical sibling after relapse of stage IV alveolar rhabdomyosarcoma. Both patients were transplanted in a non-remission status. After alloSCT both patients experienced disease progression at the primary tumor location sites and died due to the underlying disease 146 and 379 days after transplantation. The authors conclude that an alloSCT derived graft versus tumor effect might not be effective enough to overcome alveolar rhabdomyosarcoma when transplantation is carried out in a nonremission status.
Doelken
Regina
R
Department of Pediatric Hematology and Oncology, University of Greifswald, Soldmannstrasse 15, 17487 Greifswald, Germany. regina.doelken@web.de
Weigel
Steffen
S
Schueler
Frank
F
Doelken
Gottfried
G
Beck
James F
JF
D000293:Adolescent; D002648:Child; D018450:Disease Progression; D017809:Fatal Outcome; D005858:Germany / Q000453:epidemiology; D020350:Graft vs Tumor Effect / Q000187:drug effects / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D012008:Recurrence; D018232:Rhabdomyosarcoma, Alveolar / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D016896:Treatment Outcome